Who is sponsoring NCT05458258?

NCT05458258 is sponsored by University of Chicago.

What drugs are being tested in NCT05458258?

Interventions in NCT05458258: Bioelectrical Impedence Analysis Device, 6 Minute Walk Test, Computed Tomography Scans to Measure Skeletal Muscular Index, Blood Test/Blood Draw, Hand Grip Strength Test.

What condition does NCT05458258 study?

NCT05458258 studies Acute Myeloid Leukemia, Leukemia, Myeloid.

Is NCT05458258 still recruiting?

NCT05458258 is currently completed. Last updated 30 April 2025.

Last reviewed 2025-04-30 · How we verify

NCT05458258

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

Completed Last updated 30 April 2025

What this trial tests

trial testing Bioelectrical Impedence Analysis Device in Acute Myeloid Leukemia in 239 participants. Completed in 18 April 2025.

Timeline

1 March 2023

Primary endpoint
18 April 2025

18 April 2025

Quick facts

Lead sponsor	University of Chicago
Status	Completed
Study type	OBSERVATIONAL
Enrollment	239
Start date	1 March 2023
Primary completion	18 April 2025
Estimated completion	18 April 2025
Sites	1 location across United States

Drugs / interventions tested

Bioelectrical Impedence Analysis Device
6 Minute Walk Test
Computed Tomography Scans to Measure Skeletal Muscular Index
Blood Test/Blood Draw
Hand Grip Strength Test

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Leukemia, Myeloid — all drugs for Leukemia, Myeloid →

Sponsor

University of Chicago

Who can join

60 and older, any sex, with Acute Myeloid Leukemia or Leukemia, Myeloid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will receive induction chemotherapy (chemotherapy given as the first treatment to help cancer go into remission) and/or cancer drugs as part of standard care for AML. By studying how these nutritional and skeletal factors, doctors leading this study hope to learn how malnutrition and sarcopenia may be able to predict certain outcomes --such as how long study participants with poor nutrition and muscle loss can live after chemotherapy- for older (age 60+) individuals with AML.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.
Niscola P, Gianfelici V, Catalano G, Giovannini M, et al · · 2024 · cited 10× · PMID 39590121 · DOI 10.3390/curroncol31110490
Advances in electrical stimulation-based therapeutic technologies for sarcopenia prevention and treatment.
Rahaman KA, Kim MJ, Jung Y, Kang SK, et al · · 2026 · PMID 41727275 · DOI 10.1016/j.bioactmat.2026.01.035

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05458258 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 30 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05458258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing